Delivery Order SPE2DB24D2101-SPE2DB25FKPDG
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $26,519.00 for SCEMBLIX 40 mg tablets (60-count units) on August 12, 2025, with completion scheduled for September 3, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $26,519.00 to AmerisourceBergen Drug Corp for the supply of SCEMBLIX 40 MG tablets (60-count units). This firm fixed-price delivery order, issued on July 14, 2025, with completion targeted for August 4, 2025, represents a competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for the supply of SCEMBLIX 40 mg tablets (60-count units) under a firm fixed-price contract. The award was issued on August 14, 2025, with an ultimate completion date of September 5, 2025, and no set-aside designation was utilized. Performance will occur at AmerisourceBergen's Corporate Office facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $13,259.50 delivery order to AmerisourceBergen Drug Corp for Scemblix 40 mg tablets (60-count units) on August 8, 2025, with an ultimate completion date of August 29, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units) under a firm fixed-price contract. The order, issued on August 22, 2025, with an ultimate completion date of September 15, 2025, represents a competitively awarded, non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is...
- The Defense Logistics Agency has awarded a delivery order valued at $26,519.00 to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units), with a completion deadline of September 26, 2025. This competitive, non-set-aside contract reflects firm fixed pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The contract will be performed at the contractor's corporate office...
- The Defense Logistics Agency (DLA) awarded a $13,259.50 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Scemblix 40 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 3, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Scemblix 40 mg tablets (60-count units) with a contract ceiling value of $39,778.50. This is a firm fixed-price delivery order with no set-aside designation, representing a competitive award to the pharmaceutical distributor. The contract is set to be completed by September 17, 2025, and performance will take place at AmerisourceBergen's corporate office location in...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,259.50 fixed-price contract is for the delivery of SCEMBLIX 40 MG TABLET UU 60S, a specialty medication. It is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This federal contract award, valued at $24,304.14, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the drug product SCEMBLIX 40 MG TABLET. It is a firm-fixed-price contract with a completion date of November 25, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKPDGDelivery Order
The Defense Logistics Agency awarded a $26,519 firm fixed-price delivery order to AmerisourceBergen Drug Corp for SCEMBLIX 40 mg tablets (60-count units) on September 3, 2025, with completion scheduled for September 24, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements with DLA, leveraging the company's extensive capabilities as a major pharmaceutical distributor to the federal healthcare system. The delivery location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026, which serves as a comprehensive pharmaceutical support mechanism for military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates consistent success in competitively awarded medical supply deliveries across multiple therapeutic domains, positioning the company as a critical vendor for Defense Health Agency and other government healthcare systems requiring specialty medications, brand-name and generic drugs, and related medical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.5k | 9/3/25 |